Zachariah Mathew, Al Zadjali Shoaib, Bashir Wafa, Al Ambusaidi Rahma, Misquith Rhea, Wali Yasser, Pathare Anil
Departments of Child Health, Sultan Qaboos University Hospital, Muscat, Oman.
Departments of Haematology, Sultan Qaboos University Hospital, Muscat, Oman.
Mediterr J Hematol Infect Dis. 2016 Feb 15;8(1):e2016013. doi: 10.4084/MJHID.2016.013. eCollection 2016.
Our aim was to study mannose-binding protein (MBP) polymorphisms in exonic and promoter region and correlate it with associated infections and vasoocculsive (VOC) episodes in sickle cell disease (SCD) patients since MBP plays an important role in innate immunity by activating the complement system.
We studied the genetic polymorphisms in the Exon 1 (alleles A/O) and promoter region (alleles Y/X; H/L, P/Q) of the MBL2 gene, in SCD patients as an increased incidence of infections is seen in these patients. A PCR-based, targeted genomic DNA sequencing of MBL2 was used to study 68 SCD Omani patients and 44 controls (healthy voluntary blood donors).
In SCD patients, the frequency of the genotype related to the high production of MBL was 0.35 (YA/YA) and for intermediate/low production was 0.65 (YA/XA, XA/XA, YA/YO, XA/YO, YO/YO). The observed frequencies of MBL2 gene promoter polymorphism (-221, Y/X) were 44.4% and 20.5% for the heterozygous genotype Y/X and 3.2% and 2.2% for the homozygous (X/X) respectively between SCD patients and controls. MBL2 Exon1 gene mutations were 29.4% and 50% for the heterozygous genotype A/O and 5.9% and 6.8% respectively for the homozygous (O/O) genotype between SCD patients and controls. The distribution of variant MBL2 gene polymorphisms did not show any correlation in SCD patients with or without VOC attacks (p=0.16; OR -0.486; CI=0.177 -1.33), however, it was correlated with infections (p=0.0162; OR -3.55; CI 1.25-10.04).
Although the frequency of the genotypes and haplotypes of MBL2 in SCD patients did not differ from controls, overall in the SCD patient cohort the increased representation of variant alleles was significantly correlated with infections (p<0.05). However, these variant MBL2 polymorphisms did not seem to play a significant role in the VOC episodes in this SCD cohort.
我们的目的是研究甘露糖结合蛋白(MBP)外显子和启动子区域的多态性,并将其与镰状细胞病(SCD)患者的相关感染和血管阻塞性(VOC)发作相关联,因为MBP通过激活补体系统在先天免疫中起重要作用。
我们研究了MBL2基因外显子1(等位基因A/O)和启动子区域(等位基因Y/X;H/L,P/Q)的基因多态性,因为在这些SCD患者中感染发生率增加。使用基于PCR的MBL2靶向基因组DNA测序来研究68名阿曼SCD患者和44名对照(健康自愿献血者)。
在SCD患者中,与MBL高产量相关的基因型频率为0.35(YA/YA),中等/低产量的频率为0.65(YA/XA、XA/XA、YA/YO、XA/YO、YO/YO)。SCD患者和对照之间,MBL2基因启动子多态性(-221,Y/X)杂合基因型Y/X的观察频率分别为44.4%和2(此处原文似乎有误,推测为20.5%)0.5%,纯合子(X/X)的观察频率分别为3.2%和2.2%。SCD患者和对照之间,MBL2外显子1基因突变杂合基因型A/O分别为29.4%和50%,纯合子(O/O)基因型分别为5.9%和6.8%。MBL2基因多态性变体的分布在有或无VOC发作的SCD患者中未显示任何相关性(p=0.16;OR -0.486;CI=0.177 -1.33),然而,它与感染相关(p=0.0162;OR -3.55;CI 1.25 - 10.04)。
虽然SCD患者中MBL2的基因型和单倍型频率与对照无差异,但总体而言,在SCD患者队列中,变体等位基因的增加与感染显著相关(p<0.05)。然而,这些MBL2多态性变体在该SCD队列的VOC发作中似乎未起重要作用。